Effect of Antioxidant Supplementation on the Autonomic Balance

A clinical trial was performed, with 60 individuals, 30 normotensive and 30 hypertensive patients. Participants were of both sex, aged between 18 and 60 years and Body Mass Index (BMI) less than 35 kg / m². Venous blood samples were collected after 12-hour fasting for biochemical measurements (glucose, total cholesterol and LDL-cholesterol, HDL-cholesterol, triglycerides, uric acid, sodium, potassium, urea, creatinine, insulin), and adiponectin , interleukin-4 (IL-4), interleukin-2β (IL-2β), monocyte chemoattractant protein-1 (MCP-1), leptin, C-reactive protein, tumor necrosis factor alpha (TNF-α), interleukin-6 and nitrotyrosine. An anthropometric evaluation was performed with measures of weight, height, waist circumference and cervical circumference. The hemodynamic evaluation was done through a non-invasive monitor. The study participants were divided into 2 different groups: Group A (normotensive) and Group B (hypertensive). The capsules for antioxidant supplementation were of blueberry, cranberry and pomegranate, being one capsule of each a day. Study participants received placebo capsules for 4 weeks and then received the fruit extract capsules (blueberry, cranberry and pomegranate), one capsule a day for 4 weeks. All tests were performed at baseline, after 4 and 8 weeks of intervention. The comparison between groups was performed with the Multiple Comparison Test (ANOVA). The research project was approved by the Ethics Committee for Analysis of Research Projects (CAPPesq) of the Hospital das Clinicas of the Faculty of Medicine of the University of Sao Paulo. Participation in the research was voluntary and all participants read and signed the consent form. The risk for the present participant was minimal.

Inclusion criteria

• diagnosis of hypertension - group Hypertensives
• Healthy people - group Normotensive

Exclusion criteria

• Patients with glycated hemoglobin > 7%,
• Patients with a diagnosis of cardiovascular disease,
• Patients with LDL-cholesterol> 160 mg/dL (non-diabetics)
• Pregnant women,
• Cigarret smokers,
• Diabetics using more than one drug in addition to metformin,
• Patients with LDL-cholesterol> 130 mg/dL (non-diabetic using statin),
• LDL cholesterol ≥ 100 mg / dL (patients on statin),
• Patients with valvular heart disease,
• Pulmonary hypertension,
• Patients with collagen disease,
• Patients with type of cancer,
• Complex arrhythmia,
• Those patients with any chronic crippling pathology.